HCW9218 for Advanced Solid Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called HCW9218 for individuals with advanced solid cancers, excluding pancreatic and primary brain cancers. The study aims to determine the optimal dose of HCW9218, which boosts the immune system and blocks proteins that promote tumor growth. This trial may suit those who have tried at least two treatments without success and still have measurable symptoms. Participants will receive the treatment through a simple injection every three weeks. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use St. John's wort or other herbal CYP modulators starting 7 days before the trial and during the study. Also, if you have an autoimmune disease requiring treatment with certain medications, you may not be eligible.
Is there any evidence suggesting that HCW9218 is likely to be safe for humans?
Research has shown that HCW9218, a new treatment for advanced solid tumors, generally has a manageable safety profile in early studies. While side effects may occur, most patients can tolerate them. The main goal of these studies was to determine the highest dose patients can take without serious issues. So far, HCW9218 has not shown any unexpected or major safety problems. However, as testing continues, ongoing research will closely monitor its safety.12345
Why do researchers think this study treatment might be promising?
Unlike the standard treatments for advanced solid cancers, which often involve chemotherapy, radiation, or surgery, HCW9218 is a unique option because it is a biologic agent administered as a subcutaneous injection. HCW9218 works by harnessing the immune system to fight cancer cells, potentially offering a more targeted approach with fewer side effects. Researchers are particularly excited about its novel mechanism of action, which involves modulating immune responses to enhance the body’s natural ability to combat cancer. This could pave the way for a new generation of cancer therapies that are more effective and less taxing on patients.
What evidence suggests that HCW9218 might be an effective treatment for advanced solid cancers?
Research has shown that HCW9218 might help treat advanced solid tumors. Early results suggest that HCW9218 strengthens the body's immune system to fight cancer. It activates certain immune cells and blocks TGF-β, a protein that can promote cancer growth. Studies have found that HCW9218 improves the effectiveness of chemotherapy in fighting tumors. So far, patients have tolerated the treatment well, even at higher doses.12467
Who Is on the Research Team?
Melissa Geller, MD
Principal Investigator
Masonic Cancer Center, Univeristy of Minnesota
Are You a Good Fit for This Trial?
Adults with advanced solid tumors (excluding pancreatic and primary brain cancers) who have tried at least two treatments without success. They must be in fairly good health, not planning to get pregnant, and agree to use contraception. People can't join if they've had certain heart issues, untreated brain metastases, recent cancer treatment or other specific medical conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive HCW9218 as monotherapy at assigned dose by SC injection once every 3 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- HCW9218
Find a Clinic Near You
Who Is Running the Clinical Trial?
Masonic Cancer Center, University of Minnesota
Lead Sponsor